Summary of Champions Oncology Q1 2027 Earnings Call

1Key Financial Results and Metrics

Revenue: $15.2 million, a 9% increase from $14 million in Q1 FY26.

Gross Margin: Improved to 50% from 43% in the prior year.

Adjusted EBITDA: Approximately $700,000, marking the fifth consecutive quarter of positive adjusted EBITDA.

Net Loss: $426,000, slightly improved from a loss of $527,000 in Q1 FY26.

Cash Position: Ended the quarter with $4.4 million in cash and no debt; approximately $500,000 cash used during the quarter primarily due to working capital movements.

2Strategic Updates and Business Highlights

Translational Oncology Services (TOS): Generated $14.3 million in revenue, with stable margins and strong demand for predictive modeling services.

Data Licensing Revenue: $893,000 in Q1, exceeding total revenue for all of FY26, attributed to a broader customer base developed over the past year.

Corellia: Continued positive discussions with potential partners and venture groups, with ongoing data generation strengthening the business case.

3Forward Guidance and Outlook

The company remains optimistic about the trajectory of growth, emphasizing that fiscal 2026 was an investment year, and Q1 FY27 shows signs of those investments paying off.

Management plans to maintain focus on revenue growth while expanding profitability and will continue to report progress in upcoming quarters.

4Bad News, Challenges, or Points of Concern

Net Loss: Despite improvements, the company still reported a net loss, indicating ongoing challenges in achieving profitability.

Cash Utilization: The use of cash during the quarter raises questions about liquidity management, especially with a relatively low cash balance.

Revenue Lumps: Data licensing revenue is expected to remain "lumpy," which could lead to variability in future earnings.

5Notable Q&A Insights

There were no questions from analysts during the call, indicating either satisfaction with the information provided or a lack of immediate concerns from the investment community. Overall, Champions Oncology's Q1 FY27 results reflect a positive trajectory with improved revenue and margins, although challenges remain in achieving consistent profitability and managing cash flow. The company is focused on leveraging its investments from the previous year to drive future growth.